#ExistRefRange>Greater than or equal to 67 percent.
#ExistInterpData>Microtiter plates coated with monoclonal anti-ADAMTS13 antibody are used to measure ADAMTS13 activity by Fluorescence Resonance Energy Transfer (FRET).
ADAMTS13 levels of less than 5% may be associated with either inherited (Upshaw-Schulman Syndrome) or acquired thrombotic thrombocytopenic purpura (TTP).
A variety of medical conditions may result in a mild to moderate deficiency of ADAMTS13 activity. Recent plasma exchange therapy may raise the observed ADAMTS13 activity.
The monoclonal anti-ADAMTS13 antibody is directed against the CUB domain; therefore, certain forms of ADAMTS13 (with mutations in the CUB domains) may not be equivalently measured due to reduced binding to the antibody.
See Compliance Statement D: www.aruplab.com/CS
||von Willebrand Factor Cleaving Protease (ADAMTS13 Activity)